{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:03:38Z","timestamp":1777431818129,"version":"3.51.4"},"reference-count":34,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Antithrombotic drugs are consistently involved in medication-related adverse events (MRAEs) in hospitalized patients. We aimed to estimate the antithrombotic-related adverse event (ARAE) incidence between 2008 and 2016 and analyse their clinical context in hospitalized patients in The Netherlands. A post-hoc analysis of three national studies, aimed at adverse event (AE) identification, was performed. Previously identified AEs were screened for antithrombotic involvement. Crude and multi-level, case-mix adjusted ARAE and MRAE incidences were calculated. Various contextual ARAE characteristics were analysed. ARAE incidence between 2008 and 2016 decreased significantly in in-hospital deceased patients from 1.20% (95% confidence interval (CI): 0.63\u20132.27%) in 2008 to 0.54% (95% CI: 0.27\u20131.11%) in 2015\/2016 (p = 0.02). In discharged patients ARAE incidence remained stable. By comparison, overall MRAE incidence remained stable for both deceased and discharged patients. Most ARAEs involved Vitamin-K antagonists (VKAs). Preventable ARAEs occurred more during weekends and with increasing multidisciplinary involvement. Antiplatelet and combined antithrombotic use seemed to be increasingly involved in ARAEs over time. ARAE incidence declined by 55% in deceased patients between 2008 and 2016. Opportunities for improving antithrombotic safety should target INR monitoring and care delivery aspects such as multidisciplinary involvement and weekend care. Future ARAE monitoring for the involvement of antiplatelet, combined antithrombotic and direct oral anticoagulant (DOAC) use is recommended.<\/jats:p>","DOI":"10.3390\/jcm8060839","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T10:55:19Z","timestamp":1560336919000},"page":"839","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Occurrence of Antithrombotic Related Adverse Events in Hospitalized Patients: Incidence and Clinical Context between 2008 and 2016"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3546-760X","authenticated-orcid":false,"given":"Marco J.","family":"Moesker","sequence":"first","affiliation":[{"name":"Department of Public and Occupational Health, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, De Boelelaan 1117, 1081 BT Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8957-4590","authenticated-orcid":false,"given":"Bernadette C.F.M.","family":"Schutijser","sequence":"additional","affiliation":[{"name":"Department of Public and Occupational Health, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, De Boelelaan 1117, 1081 BT Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janke F.","family":"de Groot","sequence":"additional","affiliation":[{"name":"Netherlands Institute for Health Services Research (NIVEL), 3513 CR Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaike","family":"Langelaan","sequence":"additional","affiliation":[{"name":"PinkRoccade healthcare, 7324 AE Apeldoorn, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Spreeuwenberg","sequence":"additional","affiliation":[{"name":"Netherlands Institute for Health Services Research (NIVEL), 3513 CR Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1423-5348","authenticated-orcid":false,"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1838-1158","authenticated-orcid":false,"given":"Martine C.","family":"de Bruijne","sequence":"additional","affiliation":[{"name":"Department of Public and Occupational Health, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, De Boelelaan 1117, 1081 BT Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cordula","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Public and Occupational Health, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, De Boelelaan 1117, 1081 BT Amsterdam, The Netherlands"},{"name":"Netherlands Institute for Health Services Research (NIVEL), 3513 CR Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,12]]},"reference":[{"key":"ref_1","unstructured":"Kessler, C.M., and Konkle, B.A. (2013). 26\u2014Antithrombotic Agents A2\u2014Kitchens, Craig, S. Consultative Hemostasis and Thrombosis, W.B. Saunders. [3rd ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(15)60243-4","article-title":"Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments","volume":"386","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ehjcvp\/pvv014","article-title":"Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel","volume":"1","author":"Rohla","year":"2015","journal-title":"Eur. Hear. J. Cardiovasc. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.thromres.2008.08.012","article-title":"Concomitant antiplatelet and anticoagulation therapy: Indications, controversies and practical advice","volume":"123","author":"Dowd","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding complications with warfarin use: A prevalent adverse effect resulting in regulatory action","volume":"167","author":"Wysowski","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.5603\/KP.2016.0172","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"74","author":"Kirchhof","year":"2016","journal-title":"Kardiologia Polska"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/th14-12-1050","article-title":"Combined assessment of thrombotic and haemorrhagic risk in acute medical patients","volume":"115","author":"Orlandini","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0037-1616088","article-title":"Characteristics of Anticoagulant Therapy and Comorbidity Related to Overanticoagulation","volume":"86","author":"Beest","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/pds.693","article-title":"Adverse drug events in hospitalized patients treated with cardiovascular drugs and anticoagulants","volume":"11","author":"Zaidenstein","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/11536800-000000000-00000","article-title":"Nature, occurrence and consequences of medication-related adverse events during hospitalization: A retrospective chart review in The Netherlands","volume":"33","author":"Hoonhout","year":"2010","journal-title":"Drug Safety"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17843286.2017.1283759","article-title":"A multicenter record review of in-hospital adverse drug events requiring a higher level of care","volume":"72","author":"Marquet","year":"2017","journal-title":"Acta Clin. Belg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1001\/archinte.161.19.2317","article-title":"Drug-Related Deaths in a Department of Internal Medicine","volume":"161","author":"Ebbesen","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00228-014-1668-z","article-title":"Identifying high-risk medication: a systematic literature review","volume":"70","author":"Saedder","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00228-017-2330-3","article-title":"The prevalence of medication-related adverse events in inpatients\u2014a systematic review and meta-analysis","volume":"73","author":"Laatikainen","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/MLR.0000000000000780","article-title":"The Marginal Costs of Adverse Drug Events Associated With Exposures to Anticoagulants and Hypoglycemic Agents During Hospitalization","volume":"55","author":"Spector","year":"2017","journal-title":"Med Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11606-009-1141-3","article-title":"Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention","volume":"25","author":"Hug","year":"2010","journal-title":"J. Gen. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/OGX.0b013e3182021fe9","article-title":"Effect of Bar-Code Technology on the Safety of Medication Administration","volume":"65","author":"Poon","year":"2010","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmjqs-2014-003702","article-title":"How effective are patient safety initiatives? A retrospective patient record review study of changes to patient safety over time","volume":"24","author":"Baines","year":"2015","journal-title":"BMJ Qual. Saf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/bmjqs-2012-001126","article-title":"Changes in adverse event rates in hospitals over time: a longitudinal retrospective patient record review study","volume":"22","author":"Baines","year":"2013","journal-title":"BMJ Qual. Saf."},{"key":"ref_24","unstructured":"Langelaan, M., Broekens, M.A., Bruijne de, M.C., Groot de, J.F., Moesker, M.J., Porte, P.J., Schutijser, B., Singotani, R., Smits, M., and Zwaan, L. (2017). Monitor zorggerelateerde schade 2015\/2016: Dossieronderzoek bij overleden pati\u00ebnten in Nederlandse ziekenhuizen, Netherlands Institute for Health Services Research(NIVEL)."},{"key":"ref_25","unstructured":"Klopotowska, J., Schutijser, B., Bruijne, M.D., and Wagner, C. (2016). Tweede evaluatie van het VMS veilgheidprogramma, NIVEL en EMGO+ instituut."},{"key":"ref_26","unstructured":"(2018). Samenvatting Medische Jaarverslagen 2017, Federatie Nederlandse Trombosediensten."},{"key":"ref_27","unstructured":"(2016). Verdubbeling van gebruik nieuwe antistollingsmiddelen. Pharmaceutisch Weekblad, 151, 14."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic Overview of Warfarin and Its Drug and Food Interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_29","first-page":"4383","article-title":"Excessive anticoagulation with warfarin or phenprocoumon may have multiple causes","volume":"59","author":"Meegaard","year":"2012","journal-title":"Dan. Med J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1503\/cmaj.131568","article-title":"Deprescribing: a new word to guide medication review","volume":"186","author":"Frank","year":"2014","journal-title":"Can. Med Assoc. J."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Farrell, B., Pottie, K., Rojas-Fernandez, C.H., Bjerre, L.M., Thompson, W., and Welch, V. (2016). Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161248"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJMsa003376","article-title":"Mortality among Patients Admitted to Hospitals on Weekends as Compared with Weekdays","volume":"345","author":"Bell","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_33","first-page":"664","article-title":"Adverse drug events caused by medication errors in medical inpatients","volume":"134","author":"Hardmeier","year":"2004","journal-title":"Swiss Med Wkly."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e00307","DOI":"10.1002\/prp2.307","article-title":"Medication errors involving anticoagulants: Data from the Danish patient safety database","volume":"5","author":"Henriksen","year":"2017","journal-title":"Pharmacol. Res. Perspect."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/6\/839\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:57:53Z","timestamp":1760187473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/6\/839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,12]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["jcm8060839"],"URL":"https:\/\/doi.org\/10.3390\/jcm8060839","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,12]]}}}